AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Neurocrine Biosciences In... (NBIX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

113.85

-1.17 (-1.02%)

At close: Feb 18, 2025, 3:59 PM

113.97

0.11%

After-hours: Feb 18, 2025, 04:42 PM EST

undefined% (undefined)

Bid	110
Market Cap	11.35B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	3.29
PE Ratio (ttm)	34.6
Forward PE	n/a
Analyst	Buy

Ask	122.22
Volume	723,686
Avg. Volume (20D)	1,169,523
Open	115.22
Previous Close	115.02
Day's Range	113.02 - 115.82
52-Week Range	110.95 - 157.98
Beta	undefined

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 23, 1996

Employees 1,800

Stock Exchange NASDAQ

Ticker Symbol NBIX

Website https://www.neurocrine.com

Full Company Profile

Analyst Forecast

According to 21 analyst ratings, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $167.5, which is an increase of 47.12% from the latest price.

Buy 80.95%

Hold 19.05%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Neurocrine Biosciences Inc. is scheduled to release its earnings on Apr 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-3.11%

Neurocrine Biosciences shares are trading lower af... Unlock content with Pro Subscription

1 week ago

-18.53%

Neurocrine Biosciences shares are trading lower after the company missed its Q4 revenue estimate when reporting financial results. Additionally, HC Wainwright & Co. and B of A Securities lowered their respective price targets on the stock.

News

1 week ago · fool.com

Why Neurocrine Biosciences Stock Sank Today

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn't been wowing analysts lately. On Monday, no less than thr...

1 week ago · benzinga.com

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56.

1 week ago · fool.com

Neurocrine Biosciences Reports Mixed Q4

Neurological therapeutics specialist Neurocrine Biosciences (NBIX -0.46%) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnin...

1 week ago · seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Execu...

1 week ago · zacks.com

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.44 per share a year ago.

2 weeks ago · zacks.com

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr...

2 weeks ago · seekingalpha.com

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment for CA...

2 weeks ago · zacks.com

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · https://thefly.com

Neurocrine price target raised to $182 from $172 at BofA

BofA analyst Tazeen Ahmad raised the firm's price target on Neurocrine to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S. prices...

2 months ago · seekingalpha.com

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transf...

Load More News